Opinion|Videos|July 30, 2024
Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications
The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Briefly discuss insights regarding emerging resistance data and its potential implications on treatment decisions/practices.
- In patients who progress on 1L therapy with BTKi, do you test for the presence of BTK resistance mutations?
- How do you interpret available data to the clinical practice setting?
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
3
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
4
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
5